These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17153140)

  • 41. Fragment-based lead discovery using X-ray crystallography.
    Hartshorn MJ; Murray CW; Cleasby A; Frederickson M; Tickle IJ; Jhoti H
    J Med Chem; 2005 Jan; 48(2):403-13. PubMed ID: 15658854
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fragment-based lead discovery: leads by design.
    Carr RA; Congreve M; Murray CW; Rees DC
    Drug Discov Today; 2005 Jul; 10(14):987-92. PubMed ID: 16023057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In silico fragment screening by replica generation (FSRG) method for fragment-based drug design.
    Fukunishi Y; Mashimo T; Orita M; Ohno K; Nakamura H
    J Chem Inf Model; 2009 Apr; 49(4):925-33. PubMed ID: 19354203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
    Liu Q; Huang F; Yuan X; Wang K; Zou Y; Shen J; Xu Y
    J Med Chem; 2017 Dec; 60(24):10231-10244. PubMed ID: 29193967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fragment screening purely with protein crystallography.
    Spurlino JC
    Methods Enzymol; 2011; 493():321-56. PubMed ID: 21371597
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid Elaboration of Fragments into Leads by X-ray Crystallographic Screening of Parallel Chemical Libraries (REFiL
    Bentley MR; Ilyichova OV; Wang G; Williams ML; Sharma G; Alwan WS; Whitehouse RL; Mohanty B; Scammells PJ; Heras B; Martin JL; Totsika M; Capuano B; Doak BC; Scanlon MJ
    J Med Chem; 2020 Jul; 63(13):6863-6875. PubMed ID: 32529824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fragment based drug design: from experimental to computational approaches.
    Kumar A; Voet A; Zhang KY
    Curr Med Chem; 2012; 19(30):5128-47. PubMed ID: 22934764
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification?
    Wielens J; Headey SJ; Rhodes DI; Mulder RJ; Dolezal O; Deadman JJ; Newman J; Chalmers DK; Parker MW; Peat TS; Scanlon MJ
    J Biomol Screen; 2013 Feb; 18(2):147-59. PubMed ID: 23139382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of fragment-based n-FABS NMR screening applied to the membrane enzyme FAAH.
    Lambruschini C; Veronesi M; Romeo E; Garau G; Bandiera T; Piomelli D; Scarpelli R; Dalvit C
    Chembiochem; 2013 Sep; 14(13):1611-9. PubMed ID: 23918626
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficient exploration of chemical space by fragment-based screening.
    Hall RJ; Mortenson PN; Murray CW
    Prog Biophys Mol Biol; 2014; 116(2-3):82-91. PubMed ID: 25268064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fragment informatics and computational fragment-based drug design: an overview and update.
    Sheng C; Zhang W
    Med Res Rev; 2013 May; 33(3):554-98. PubMed ID: 22430881
    [TBL] [Abstract][Full Text] [Related]  

  • 53. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
    Giannetti AM
    Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fragment based drug discovery using fluorescence correlation: spectroscopy techniques: challenges and solutions.
    Hesterkamp T; Barker J; Davenport A; Whittaker M
    Curr Top Med Chem; 2007; 7(16):1582-91. PubMed ID: 17979769
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Virtual Screening of Novel Glucosamine-6-Phosphate Synthase Inhibitors.
    Lather A; Sharma S; Khatkar A
    Comb Chem High Throughput Screen; 2018; 21(3):182-193. PubMed ID: 29600755
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel approach of fragment-based lead discovery applied to renin inhibitors.
    Tawada M; Suzuki S; Imaeda Y; Oki H; Snell G; Behnke CA; Kondo M; Tarui N; Tanaka T; Kuroita T; Tomimoto M
    Bioorg Med Chem; 2016 Nov; 24(22):6066-6074. PubMed ID: 27720325
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The rise of fragment-based drug discovery.
    Murray CW; Rees DC
    Nat Chem; 2009 Jun; 1(3):187-92. PubMed ID: 21378847
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery.
    Gozalbes R; Carbajo RJ; Pineda-Lucena A
    Curr Med Chem; 2010; 17(17):1769-94. PubMed ID: 20345344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fragment-based drug design.
    Feyfant E; Cross JB; Paris K; Tsao DH
    Methods Mol Biol; 2011; 685():241-52. PubMed ID: 20981527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NMR screening in fragment-based drug design: a practical guide.
    Kim HY; Wyss DF
    Methods Mol Biol; 2015; 1263():197-208. PubMed ID: 25618347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.